Regenerative Medicine and Cell Therapies Virtual Event, page-25

David is a former staffer in the White House- so he chose his words wisely. It all depends on whether or not the COVID ARDS trial is successful or not, but if it is- I don’t think David would be so vague about his response if the White House called him up and asked him exactly what they could do to get remestemcel-l produced in quantities that could service the demand in the US.

Australia will be asking the same question.

John said one of the largest bottlenecks would be sourcing enough raw materials, and the need to get access to sites ready to produce MSCs. He suggested collaboration among all industry players would be required to get enough produced to meet US demand.

I took that to mean that anyone with a lab that was capable of producing MSCs in the US may need to be utilised ... like how companies were asked to produce ventilators in the US and businesses in Australia converted their businesses to produce hand sanitizers... this is not something MSB can achieve on its own.. it needs a lot of funds, and industry help to mass produce enough remestemcel-l.